Fig. 7: TMZ and radiation change GBM immune microenvironment and prolong survival.
From: Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
a, Flow cytometry of BM and spleens of control non-GBM-bearing mice and early-stage (BLI 107 p s−1 cm−2 sr−1) GBM mice for the indicated cell type and progenitors. Data are represented as mean ± s.e.m. of biologically independent replicates. Comparisons between control (n = 4) and GBM (n = 4) mice. *P = 0.0266, **P = 0.015, ***P = 0.0081, ****P = 0.0139 and *****P = 0.0002, unpaired t test, two-tailed. b, Flow cytometry of spleen cells as in a for the indicated cell markers and checkpoint molecules. Data are represented as mean ± s.e.m. of biologically independent replicates. Comparisons between control (n = 4) and GBM-bearing (n = 4) mice, *P = 0.0491, **P = 0.0094, ***P = 0.0087, ****P = 0.0053, *****P = 0.0001 and ******P < 0.0001, unpaired t test, two-tailed. c, Kaplan–Meier survival analysis of GBM mice treated with control vehicle or 25 or 66.7 mg kg−1 TMZ daily. TMZ 66.7 g kg−1 versus control *P < 0.0001, NS, not significant, log-rank (Mantel–Cox). Data are represented from biologically independent replicates, n = 13, 6 and 7 for control, 25 and 66.7 mg kg−1 TMZ, respectively. d, Flow cytometry for the indicated cell types from GBM of control and TMZ-treated (25 mg kg−1 or 66.7 mg kg−1 daily) mice. Comparisons of control and TMZ-treated. Data are represented as mean ± s.e.m. of biologically independent replicates, n = 5, 3, and 5 for control, 25.0 and 66.7 mg kg−1 TMZ respectively, *P = 0.0051, **P = 0.0074, ***P = 0.0194, unpaired t test, two-tailed. e, Kaplan–Meier survival analysis of GBM mice treated with control vehicle, 25 mg kg−1 TMZ, IR and IR/TMZ as indicated. Data represent biologically independent replicates, n = 13, 6, 4 and 5 for control, 25 mg kg−1 TMZ, IR and IR/TMZ, respectively. *P < 0.0001 log-rank (Mantel–Cox). f, Flow cytometry of GBMs for the indicated cell type from control and TMZ (25 mg kg−1), IR (2 Gy/day) and IR/TMZ-treated GBM mice. Comparisons of control and treatment. Data represent mean ± s.e.m. of biologically independent tumors. Microglia/macrophages, PMN-MDSCs/M-MDSCs and CD45+/EGFR+ panels n = 7, 4, 6, 3 for control, TMZ, IR and IR/TMZ, respectively. *P = 0.0397, **P = 0.0456, ***P = 0.0487, ****P = 0.034, unpaired t test, two-tailed. CD4+/CD8+/Tregs/GranB+CD8+ panel n = 4, 4, 3, 3, for control, TMZ, IR and IR/TMZ, respectively of the *P = 0.0125, **P = 0.0065, ***P = 0.0049, ****P = 0.0054, *****P = 0.0026. Unpaired t test, two-tailed.
